『#310 - Can We Measure Aging Well Enough to Treat It? | Dr. Nir Barzilai & Mike Haney』のカバーアート

#310 - Can We Measure Aging Well Enough to Treat It? | Dr. Nir Barzilai & Mike Haney

#310 - Can We Measure Aging Well Enough to Treat It? | Dr. Nir Barzilai & Mike Haney

無料で聴く

ポッドキャストの詳細を見る

【Amazonプライム会員限定】今ならプレミアムプランが4か月 月額99円。

10月19日まで。※適用条件あり
Aging science has gotten much better at describing who appears to be aging faster or slower. What medicine still lacks is a reliable feedback loop: a way to tell whether something we do is actually changing the biology that drives age-related disease.Dr. Nir Barzilai argues that solving that measurement problem could turn geroscience from an interesting field of research into something doctors can actually use: measure where you are, intervene, measure again, and learn what works.Free course: Improve your metabolic healthGet our free email course on how glucose, nutrition, exercise, sleep, and measurement can help you build habits that support better energy and long-term health: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://levels.link/wnl⁠What We Cover:What centenarians reveal about living longer and spending less time sickWhy changing one hallmark of aging can affect several othersHow TAME was designed to test metformin as an anti-aging drug and to convince the FDA to treat aging itself as an endpoint—and why it failed to get off the groundWhy metformin, SGLT2 inhibitors, GLP-1 agonists, and some osteoporosis drugs are being studied as potential gerotherapeutics, or anti-aging drugsHow FAST is searching existing clinical trials for biomarkers that change when an intervention affects aging biologyWhether aging needs continuous monitoring or can be meaningfully tracked a few times a year🎙️ About the Guest:Dr. Nir Barzilai is the Ingeborg and Ira Leon Rennert Chair in Aging Research and a professor of medicine and genetics at Albert Einstein College of Medicine, where he directs the Institute for Geroscience. 📍What Dr. Nil Barzilai & Mike Haney discussed:05:10 - Aging is a condition, not just a label05:59 - Why aging is what drives disease08:19 - Should we call aging a disease?10:20 - Why the species may have a ceiling around 11514:34 - Why changing one hallmark of aging changes the others23:08 - Metformin was anti-aging before it was a diabetes drug31:55 - Centenarians live longer and spend less time sick40:12 - How TAME tried to make aging an FDA endpoint48:17 - Metformin, SGLT2s, GLP-1s, and osteoporosis drugs as gerotherapeutics52:26 - FAST: finding biomarkers that actually change with treatment56:49 - Whether aging needs continuous monitoring, or a few checks a year1:01:16 - Where behavior still fits once we have anti-aging drugs🔗 Helpful Links:Hallmarks of Aging: An Expanding Universe (Cell, 2023) PaperCompression of Morbidity Is Observed Across Cohorts with Exceptional Longevity (JAGS, 2016) PaperMetformin as a Tool to Target Aging (Cell Metabolism, 2016) PaperGeroscience-Guided Repurposing of FDA-Approved Drugs to Target Aging (Aging Cell, 2022) PaperBiomarkers of Aging for the Identification and Evaluation of Longevity Interventions (Cell, 2023) PaperFAST: Finding Aging Biomarkers by Searching Existing Trials FAST InitiativeARPA-H PROSPR / FAST award ARPA-H FAST projectWatch the conversation: https://youtu.be/HbeGjwCw6vkFind us on YouTube: ⁠⁠⁠⁠⁠⁠⁠⁠https://youtube.com/levelshealth?sub_confirmation=1⁠⁠⁠⁠⁠⁠⁠📲 Connect:Connect with Dr. Nil Barzilai on X: https://x.com/NirBarzilaiMD👋 Who we are:Levels helps you understand your metabolic health with personalized data, expert guidance, and tools that connect your daily choices to measurable changes in your body. Our goal is to help you make better decisions about food, exercise, sleep, and long-term health.Look for new shows every month on A Whole New Level, where we have in-depth conversations with thought leaders about metabolic health.
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません